Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B03XA01

Eporatio(epoetin theta)

Kidney Failure, Chronic;Anemia;Cancer

Marketing Authorisation Holder: Ratiopharm GmbH

EMA Authorisation: 29/10/2009

INN: epoetin theta

Indication

Treatment of symptomatic anaemia associated with chronic renal failure in adult patients. Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Eporatio — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.